Citations (44)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, Francesco Bandello & Baruch D. Kuppermann. (2023) Immunogenicity: Clouding the Future of Intravitreal Therapy. Ocular Immunology and Inflammation 31:9, pages 1746-1749.
Read now
Read now
Kyuhwan Jang, Jayoung Ahn, Joonhong Sohn & Daniel Duck-Jin Hwang. (2020) Evaluation of the Safety of Bilateral Same-Day Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents: Experience of a Large Korean Retina Center. Clinical Ophthalmology 14, pages 3211-3218.
Read now
Read now
Jaycob Avaylon, Sol Lee & Ron P Gallemore. (2020) Case Series on Initial Responses to Intravitreal Brolucizumab in Patients with Recalcitrant Chronic Wet Age-Related Macular Degeneration. International Medical Case Reports Journal 13, pages 145-152.
Read now
Read now
Jared E. Knickelbein, Emily Y. Chew & H. Nida Sen. (2016) Intraocular Inflammation Following Intravitreal Injection of Anti-VEGF Medications for Neovascular Age-Related Macular Degeneration. Ophthalmic Epidemiology 23:2, pages 69-70.
Read now
Read now
Articles from other publishers (40)
Amit V. Mishra, C. Maya Tong, Livia Faes, Marvi K. Cheema, David Plemel, Uriel Rubin, Bo Bao, Samir Nazarali, Steven R.J. Lapere, Rizwan Somani, Brad J. Hinz & Matthew T.S. Tennant. (2023) Comparison of Endophthalmitis Rates after Alcohol-Based Chlorhexidine and Povidone-Iodine Antisepsis for Intravitreal Injections. Ophthalmology Retina.
Crossref
Crossref
Badiaa El Karmy, Daniela Gallo Castro & Aude Ambresin. (2023) Preventive Inflammation Management with Steroids before Retreatment with Anti-VEGF after Severe Inflammation due to Brolucizumab. Klinische Monatsblätter für Augenheilkunde 240:04, pages 556-562.
Crossref
Crossref
Monika Kapur, Suvansh Nirula & Mayuresh P. Naik. (2022) Future of anti-VEGF: biosimilars and biobetters. International Journal of Retina and Vitreous 8:1.
Crossref
Crossref
Martin Busch, Johanna M. Pfeil, Merlin Dähmcke, Tara Brauckmann, Rico Großjohann, Viola Chisci, Elisabeth Hunfeld, Sonja Eilts, Wael Omran, Ewa Morawiec‐Kisiel, Daniel Schulz, Sebastian Paul, Allam Tayar, Marie‐Christine Bründer, Bastian Grundel, Martin Küstner & Andreas Stahl. (2022) Anti‐drug antibodies to brolucizumab and ranibizumab in serum and vitreous of patients with ocular disease. Acta Ophthalmologica 100:8, pages 903-910.
Crossref
Crossref
Uwe Wessels, Markus Zadak, Anja Manuela Weidmann, Thomas Stuchly & Kay-Gunnar Stubenrauch. (2022) Preclinical Observations of Systemic and Ocular Antidrug Antibody Response to Intravitreally Administered Drugs. The AAPS Journal 25:1.
Crossref
Crossref
Pan Ma, Xinmei Pan, Ruixiang Liu, Ya Qu, Linli Xie, Jiangchuan Xie, Liya Cao & Yongchuan Chen. (2022) Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS). Frontiers in Pharmacology 13.
Crossref
Crossref
Rohan Merani, Mark W. Johnson, Colin A. McCannel, Harry W. FlynnJrJr, Ingrid U. Scott & Alex P. Hunyor. (2022) Clinical Practice Update: Management of Infectious Endophthalmitis After Intravitreal Anti-VEGF Injection. Journal of VitreoRetinal Diseases 6:6, pages 443-451.
Crossref
Crossref
A. Fonollosa, R. Gallego-Pinazo, L. Sararols, A. Adán, M. López-Gálvez & M.S. Figueroa. (2022) Guidance on brolucizumab management recommendations. Archivos de la Sociedad Española de Oftalmología (English Edition) 97:11, pages 626-638.
Crossref
Crossref
A. Fonollosa, R. Gallego-Pinazo, L. Sararols, A. Adán, M. López-Gálvez & M.S. Figueroa. (2022) Guía de recomendaciones para el manejo de brolucizumab. Archivos de la Sociedad Española de Oftalmología 97:11, pages 626-638.
Crossref
Crossref
Hyo Jin Seong, Young Min Park, Jiwon Kim, Kang Ju Son & Eun Jee Chung. (2022) Incidence of Acute Endophthalmitis after Intravitreal Antivascular Endothelial Growth Factor Injection in Age-related Macular Degeneration. Korean Journal of Ophthalmology 36:5, pages 435-442.
Crossref
Crossref
Jason A. Zehden, Xavier M. Mortensen, Ashvini Reddy & Alice Yang Zhang. (2022) Systemic and Ocular Adverse Events with Intravitreal Anti-VEGF Therapy Used in the Treatment of Diabetic Retinopathy: a Review. Current Diabetes Reports 22:10, pages 525-536.
Crossref
Crossref
Alaa Din Abdin, Wissam Aljundi, Khalil El Jawhari, Shady Suffo, Isabel Weinstein & Berthold Seitz. (2022) First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration. Frontiers in Pharmacology 13.
Crossref
Crossref
Rupali Singh, Samaneh Davoudi & Steven Ness. (2022) Preventive factors, diagnosis, and management of injection-related endophthalmitis: a literature review. Graefe's Archive for Clinical and Experimental Ophthalmology.
Crossref
Crossref
Helio V. Neves da Silva, John Placide, Anne Duong, Yasmyne Ronquillo, Shannon McCabe & Majid Moshirfar. (2022) Ocular adverse effects of therapeutic biologics. Therapeutic Advances in Ophthalmology 14, pages 251584142110708.
Crossref
Crossref
SriniVas R. Sadda, Frank G. Holz, Giovanni Staurenghi, Alessandro Invernizzi, Jennifer Arnold & Ramin Tadayoni. (2022) The Importance of Imaging to Identify Early Signs of Intraocular Inflammation Expert Opinion for Brolucizumab. Ophthalmologica 245:6, pages 588-591.
Crossref
Crossref
Prashanth G. Iyer & Thomas A. Albini. (2022) Review of Intraocular Inflammation After Antivascular Endothelial Growth Factor Agents. International Ophthalmology Clinics 62:3, pages 35-47.
Crossref
Crossref
Ashwin Gupta, Nicholas Nosbisch, Ishan Agarwal, Anjali Patel, Sowmyanarayanan Thuppal, Chaitanya Mamillipalli, Jessi Prentice, Jaycob Avaylon, Ron Gallemore & Ramanath Bhandari. (2022) Intravitreal Brolucizumab in Patients with Aflibercept-Resistant Neovascular Age-Related Macular Degeneration. Re:GEN Open 2:1, pages 4-8.
Crossref
Crossref
Aishwarya Kundu, Chiungkuang Chen & Sreenivasu Mudumba. 2022. Handbook of Basic and Clinical Ocular Pharmacology and Therapeutics. Handbook of Basic and Clinical Ocular Pharmacology and Therapeutics
119
129
.
Bernardete Pessoa, João Leite, João Heitor, João Coelho, Sérgio Monteiro, Constança Coelho, João Figueira, Angelina Meireles & João Nuno Melo-Beirão. (2021) Vitrectomized versus non-vitrectomized eyes in diabetic macular edema response to ranibizumab—retinal layers thickness as prognostic biomarkers. Scientific Reports 11:1.
Crossref
Crossref
Youngsub Eom, Soomi Kim, Jungah Huh, Mi Young Koh, Jin Young Hwang, Boram Kang, Xiangzhe Li, Moon Sue Lee, Haeshin Lee, Hyo Myung Kim & Jong Suk Song. (2021) Self-sealing hyaluronic acid-coated 30-gauge intravitreal injection needles for preventing vitreous and drug reflux through needle passage. Scientific Reports 11:1.
Crossref
Crossref
H. Russell DayJrJr, Janice C. Law & Jennifer L. Lindsey. (2020) Risk of Infectious Endophthalmitis From a Resident-Performed Intravitreal Injection. Journal of VitreoRetinal Diseases 5:4, pages 321-325.
Crossref
Crossref
Jordi Monés, Sunil K. Srivastava, Glenn J. Jaffe, Ramin Tadayoni, Thomas A. Albini, Peter K. Kaiser, Frank G. Holz, Jean-Francois Korobelnik, Ivana K. Kim, Christian Pruente, Timothy G. Murray & Jeffrey S. Heier. (2021) Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion–Related Events with Brolucizumab. Ophthalmology 128:7, pages 1050-1059.
Crossref
Crossref
Prashanth G. Iyer & Thomas A. Albini. (2021) Drug-related adverse effects of antivascular endothelial growth factor agents. Current Opinion in Ophthalmology 32:3, pages 191-197.
Crossref
Crossref
Hye Cheong Koo, Yi-Yong Baek, Jun-Sup Choi, Young-Myeong Kim, Bokyung Sung, Min-Jung Kim, Jae Gyu Kim & Ji Chang You. (2021) Therapeutic Efficacy of a Novel Acetylated Tetrapeptide in Animal Models of Age-Related Macular Degeneration. International Journal of Molecular Sciences 22:8, pages 3893.
Crossref
Crossref
Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, Srinivas R. Sadda, Giulia Corradetti, Jeffrey Heier, Adam T. Chin, David Boyer, Pouya Dayani, Sruthi Arepalli & Peter Kaiser. (2020) Brolucizumab—early real-world experience: BREW study. Eye 35:4, pages 1045-1047.
Crossref
Crossref
Jacob T. Cox, Dean Eliott & Lucia Sobrin. (2021) Inflammatory Complications of Intravitreal Anti-VEGF Injections. Journal of Clinical Medicine 10:5, pages 981.
Crossref
Crossref
Lalit Verma, Mithun Thulasidas, Ajay Purohit, Avnindra Gupta, Ritesh Narula & Dinesh Talwar. (2021) Clinical efficacy and safety of Razumab® (CESAR) study: Our experience with the world's first biosimilar Ranibizumab. Indian Journal of Ophthalmology 69:2, pages 347.
Crossref
Crossref
Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, Rohini Sharma, Francesco Bandello, Baruch D. Kuppermann & Anat Loewenstein. (2020) Brolucizumab and immunogenicity. Eye 34:10, pages 1726-1728.
Crossref
Crossref
Caroline R. Baumal, Richard F. Spaide, Lejla Vajzovic, K. Bailey Freund, Scott D. Walter, Vishak John, Ryan Rich, Nauman Chaudhry, Rohit R. Lakhanpal, Patrick R. Oellers, Thellea K. Leveque, Bryan K. Rutledge, Mark Chittum, Tommaso Bacci, Ana Bety Enriquez, Newman J. Sund, Eric N.P. Subong & Thomas A. Albini. (2020) Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab. Ophthalmology 127:10, pages 1345-1359.
Crossref
Crossref
Ashish Sharma, Nikulaa Parachuri, Nilesh Kumar, Rohini Sharma, Francesco Bandello, Baruch D. Kuppermann & Anat Loewenstein. (2020) Brolucizumab—another anti-VEGF or beyond. Eye 34:9, pages 1499-1500.
Crossref
Crossref
Philip J. Rosenfeld & David J. Browning. (2020) Is This a 737 Max Moment for Brolucizumab?. American Journal of Ophthalmology 216, pages A7-A8.
Crossref
Crossref
Etzel Gysling. (2020) Brolucizumab. pharma-kritik 41:10.
Crossref
Crossref
Xulong Liao, Chuang Jin, Weiqi Chen, Guihua Zhang, Ling-Ping Cen, Danny Siu-Chun Ng & Haoyu Chen. (2019) Quantification of anterior chamber reaction after intravitreal injections of conbercept and ranibizumab: a pilot study. Eye 34:3, pages 595-596.
Crossref
Crossref
Mark C. Gillies, Alex P. Hunyor, Jennifer J. Arnold, Robyn H. Guymer, Sebastian Wolf, Francois L. Pecheur, Marion R. Munk & Ian L. McAllister. (2020) Macular Atrophy in Neovascular Age-Related Macular Degeneration. Ophthalmology 127:2, pages 198-210.
Crossref
Crossref
Myron Yanoff & Joseph W. Sassani. 2020. Ocular Pathology. Ocular Pathology
102
162.e6
.
Olga Cegielska & Paweł Sajkiewicz. (2019) Targeted Drug Delivery Systems for the Treatment of Glaucoma: Most Advanced Systems Review. Polymers 11:11, pages 1742.
Crossref
Crossref
Ashish Sharma, Nilesh Kumar, Baruch D. Kuppermann, Francesco Bandello & Anat Loewenstein. (2019) Biotherapeutics and immunogenicity: ophthalmic perspective. Eye 33:9, pages 1359-1361.
Crossref
Crossref
Verena R. Juncal, Carolina L.M. Francisconi, Filiberto Altomare, David R. Chow, Louis R. Giavedoni, Rajeev H. Muni, Alan R. Berger & David T. Wong. (2019) Same-Day Bilateral Intravitreal Anti-Vascular Endothelial Growth Factor Injections: Experience of a Large Canadian Retina Center. Ophthalmologica 242:1, pages 1-7.
Crossref
Crossref
Sibel Doguizi, Mehmet A. Sekeroglu, Merve Inanc, Mustafa A. Anayol & Pelin Yilmazbas. (2017) Evaluation of pain during intravitreal aflibercept injections. European Journal of Ophthalmology 28:1, pages 63-67.
Crossref
Crossref
Adrian Skelly, Hans-Joachim Carius, Vladimir Bezlyak & Fred K. Chen. (2017) Dispensing Patterns of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration: A Retrospective Cohort Study in Australia. Advances in Therapy 34:12, pages 2585-2600.
Crossref
Crossref